Product Information
ATOMOXETINE HCL 18 MG CAPSULE is a generic product labeled by Strides Pharma Inc., priced at $0.3818 per EA under NDC 64380047301. Its NADAC has been published 54 times since Sep 24, 2025.
FDA first approved this application on Feb 18, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
18 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380047301
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATOMOXETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA079021FDA Approved
2/18/2021
TE Code
AB
On Market Since
7/1/2025
Pharmacological Classes
Price Statistics
The NADAC for ATOMOXETINE HCL 18 MG CAPSULE has been published 54 times since Sep 24, 2025, and over the history we have for it it has declined 22.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3818 per EA |
|---|---|
| All-time high | $0.5340 (Feb 11, 2026) |
| All-time low | $0.3818 (Sep 23, 2026) |
| 52-week high | $0.5340 |
| 52-week low | $0.3818 |
| Median price | $0.4791 |
| Average price | $0.4729 |
| Largest weekly change | -8.5% (Jul 22, 2026) |
| Weeks tracked | 54 |
| Tracking since | Sep 24, 2025 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Atomoxetine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Norepinephrine Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATOMOXETINE HCL 18 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ATOMOXETINE HCL 18 MG CAPSULE, manufactured by Strides Pharma Inc., is $0.3818 per EA (NDC 64380047301), effective Sep 30, 2026.
How has the price of ATOMOXETINE HCL 18 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ATOMOXETINE HCL 18 MG CAPSULE has declined 22.5%. It has been tracked across 54 weekly CMS publications since Sep 24, 2025.
What are the highest and lowest recorded NADAC prices for ATOMOXETINE HCL 18 MG CAPSULE?
Since Sep 24, 2025, the NADAC for ATOMOXETINE HCL 18 MG CAPSULE has ranged from a low of $0.3818 (Sep 23, 2026) to a high of $0.5340 (Feb 11, 2026), with a median of $0.4791 per EA.
Are there cheaper alternatives to ATOMOXETINE HCL 18 MG CAPSULE?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ATOMOXETINE HCL 18 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures ATOMOXETINE HCL 18 MG CAPSULE?
ATOMOXETINE HCL 18 MG CAPSULE (NDC 64380047301) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.